The study, which assessed the pharmacokinetics, safety, tolerability and immunogenicity of AVT80 compared to Entyvio® in healthy adult ...
Looking ahead, we believe key programs in our R&D portfolio offer significant opportunities to help address substantial patient needs and drive Pfizer's growth in the coming years. I will mention some ...
Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the leading cause of liver disease worldwide, affecting one in three people.1,2 The inflammatory form of MASLD, namely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results